Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Chloroform. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroform SCHEMBL83188 | 0.97 | CYP2C9 (0.32) | CYP1A2CYP2C9HPGDMAPK1HIF1A | |
| Isopropyl Alcohol SCHEMBL6666765 | 0.91 | ALDH1A1 (0.33) | — | |
| Chloroform SCHEMBL8348906 | 0.90 | ALDH1A1 (0.38) | CYP1A2CYP2C9HPGDMAPK1HIF1A | |
| Chloroform SCHEMBL378302 | 0.89 | LMNA (0.33) | — | |
| Cyclohexane SCHEMBL11847430 | 0.88 | — | — | |
| Chloroform SCHEMBL537028 | 0.87 | ALDH1A1 (0.40) | CYP1A2CYP2C9HPGDMAPK1HIF1A | |
| Chloroform SCHEMBL7930106 | 0.86 | LMNA (0.31) | — | |
| Methyl Alcohol SCHEMBL946877 | 0.86 | ALDH1A1 (0.35) | CYP1A2CYP2C9HPGDMAPK1HIF1A | |
| Hexane SCHEMBL27647104 | 0.85 | PLA2G1B (0.41) | HSD17B10 | |
| Methylene Chloride SCHEMBL9305751 | 0.83 | CYP2C9 (0.32) | CYP1A2CYP2C9HPGDMAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111867623-B | TOLL-like receptor ligands | 英尼穆内公司 | 2024-06-04 | — | — | CN | disclosed |
| EP-3752182-B1 | TOLL-LIKE RECEPTOR LIGANDS | INIMMUNE CORP (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20230055805-A1 | TOLL-LIKE RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-02-23 | — | — | US | disclosed |
| US-20220047698-A1 | SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF | ALBERTA RES CHEMICALS INC (CA) | 2022-02-17 | — | — | US | disclosed |
| US-20210023106-A1 | TOLL-LIKE RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-28 | — | — | US | disclosed |
| EP-3752182-A1 | TOLL-LIKE RECEPTOR LIGANDS | INIMMUNE CORPORATION (US) | 2020-12-23 | — | — | EP | disclosed |
| CN-111867623-A | TOLL-like receptor ligands | 英尼穆内公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019157509-A1 | TOLL-LIKE RECEPTOR LIGANDS | INIMMUNE CORPORATION (US) | 2019-08-15 | — | — | WO | disclosed |
| EP-1521762-B1 | PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR | CORIXA CORP (US) | 2014-03-12 | — | — | EP | disclosed |
| CN-102295652-A | Improvement method for pazufloxacin mesylate synthesis process | LIAONING HISHEN LIANSHENG PHARMACEUTICAL CO LTD | 2011-12-28 | — | — | CN | disclosed |
| EP-0983286-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-2000011010-A1 | PHOSPHOGLYCOLIPID AND METHODS FOR ITS USE | CORIXA CORPORATION (US) | 2000-03-02 | — | — | WO | disclosed |
| US-6013640-A | ANTIISCHEMIC AGENTS | RIBI IMMUNOCHEM RESEARCH, INC. (US) | 2000-01-11 | — | — | US | disclosed |
| WO-1998050399-A1 | AMINOALKYL GLUCOSAMINE PHOSPHATE COMPOUNDS AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
| US-5210193-A | Bactericide | AMERICAN CYANAMID COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| EP-0172581-B1 | DISACCHARIDE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1992-05-06 | — | — | EP | disclosed |
| US-5066794-A | Coupling monosaccharides, phosphonation, protecting, deprotecting | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1991-11-19 | — | — | US | disclosed |
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0172581-A2 | Disaccharide derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230055805-A1 | TOLL-LIKE RECEPTOR LIGANDS | TLR1, TLR4, TLR6 | CYP1A2 4157/4885CYP2C9 3870/4885HPGD 3219/4885 |
| US-20210023106-A1 | TOLL-LIKE RECEPTOR LIGANDS | TLR1, TLR4, TLR6 | CYP1A2 4157/4885CYP2C9 3870/4885HPGD 3219/4885 |
| US-20220047698-A1 | SYNTHETIC INNATE IMMUNE RECEPTOR LIGANDS AND USES THEREOF | TLR3, TLR4, TLR9 | CYP1A2 4829/4885CYP2C9 4780/4885HPGD 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.